INVA Stock Performance, Insider Transaction and News

INVA - Innoviva, Inc.

Market Cap	863.35M	P/E	5.09	EPS this Y	-63.20%	Ern Qtrly Grth	-
Income	179.72M	Forward P/E	11.56	EPS next Y	21.00%	50D Avg Chg	2.00%
Sales	310.46M	PEG	0.93	EPS past 5Y	-6.33%	200D Avg Chg	4.00%
Dividend	N/A	Price/Book	1.55	EPS next 5Y	19.34%	52W High Chg	-11.00%
Recommedations	3.00	Quick Ratio	7.28	Shares Outstanding	63.23M	52W Low Chg	24.00%
Insider Own	1.59%	ROA	7.12%	Shares Float	51.14M	Beta	0.58
Inst Own	117.70%	ROE	28.97%	Shares Shorted/Prior	11.33M/13.32M	Price	13.18
Gross Margin	84.09%	Profit Margin	57.89%	Avg. Volume	669,608	Target Price	15.00
Oper. Margin	53.02%	Earnings Date	May 7	Volume	542,807	Change	-1.35%

Healthcare | Biotechnology | United States

About Innoviva, Inc.

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Innoviva, Inc. News

03/04/24	Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva
02/29/24	Innoviva Inc (INVA) Reports Growth Amidst Challenges in Q4 and Full Year 2023 Financial Results
02/29/24	Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress
02/14/24	Jim Simons Bolsters Position in Innoviva Inc with Recent Acquisition
01/10/24	If You Can Only Buy One Biotech Stock in January, It Better Be One of These 3 Names
12/30/23	Innoviva's (NASDAQ:INVA) investors will be pleased with their 29% return over the last three years
11/18/23	Insider Sell Alert: Marianne Zhen Offloads Shares of Innoviva Inc
11/14/23	Innoviva, Inc. (NASDAQ:INVA) Has Fared Decently But Fundamentals Look Uncertain: What Lies Ahead For The Stock?
11/03/23	Innoviva Inc (INVA) Reports Q3 2023 Financial Results: Net Income Drops to $82.0 Million
11/01/23	Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
11/01/23	Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea
10/18/23	Calculating The Intrinsic Value Of Innoviva, Inc. (NASDAQ:INVA)
09/19/23	Innoviva to Participate in the Cantor Global Healthcare Conference
09/18/23	XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in Adults
08/25/23	Innoviva Appoints Stephen Basso as Chief Financial Officer
08/02/23	Innoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
07/23/23	Investors in Innoviva (NASDAQ:INVA) have unfortunately lost 11% over the last year
07/11/23	Why These 7 Stocks Are the Best Ways to Play Biotech Right Now
07/11/23	Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics
07/06/23	12 Best Extremely Profitable Stocks to Buy

INVA Chatroom

UncleStock Posted - 3 days ago

$ESEA $TRMD $DAC $INVA suggested for Levermann - value screen: https://zpr.io/Zrp84A3u8AJ3

UncleStock Posted - 4 days ago

$MED $AMR $INVA $MHO suggested for $SML US S&P Small-Cap 600 Index - value screen: https://zpr.io/tQPv2

UncleStock Posted - 1 week ago

$SIGA $INVA $VYGR $HRMY suggested for Pharmaceuticals and Biotechnology - value screen: https://zpr.io/NGP6QnBCdEbN

UncleStock Posted - 2 weeks ago

$MED $SIGA $SMLR $INVA suggested for Uncle's finest - value screen: https://zpr.io/tdAdrCVaxTnP

UncleStock Posted - 2 weeks ago

$SIGA $INVA $VYGR $AMLX suggested for Pharmaceuticals and Biotechnology - value screen: https://zpr.io/NGP6QnBCdEbN

UncleStock Posted - 2 weeks ago

$MED $AMR $INVA $MHO suggested for $SML US S&P Small-Cap 600 Index - value screen: https://zpr.io/tQPv2

UncleStock Posted - 03/30/24

$SMLR $SIGA $INVA $OSUR suggested for Health Care - value screen: https://zpr.io/w3j8HS7Eft4n

UncleStock Posted - 03/29/24

$DAC $INVA $ELTK $SMLR suggested for Levermann - value screen: https://zpr.io/Zrp84A3u8AJ3

UncleStock Posted - 03/28/24

$SIGA $INVA $VYGR $HRMY suggested for $NBI US NASDAQ Biotechnology - value screen: https://zpr.io/tBVec

UncleStock Posted - 03/28/24

$SMLR $SIGA $INVA $OSUR suggested for Health Care - value screen: https://zpr.io/w3j8HS7Eft4n

UncleStock Posted - 03/28/24

$MED $AMR $INVA $MHO suggested for $SML US S&P Small-Cap 600 Index - value screen: https://zpr.io/tQPv2

Wigglyick Posted - 03/27/24

$INVA Innoviva was set up as a spinout of Theravance, Inc. with the singular purpose of acting as a receptacle for royalties from lung drugs that Theravance had developed with pharmaceutical giant GSK plc (NYSE: GSK).

UncleStock Posted - 03/27/24

$SIGA $INVA $VYGR $EGRX suggested for Pharmaceuticals and Biotechnology - value screen: https://zpr.io/NGP6QnBCdEbN

UncleStock Posted - 03/24/24

$SIGA $INVA $VYGR $HRMY suggested for $NBI US NASDAQ Biotechnology - value screen: https://zpr.io/tBVec

UncleStock Posted - 03/22/24

$SIGA $INVA $VYGR $EGRX suggested for Pharmaceuticals and Biotechnology - value screen: https://zpr.io/NGP6QnBCdEbN

JRoon71 Posted - 03/22/24

@garvey @Family23 @soccerplayer06 @TevocQuantico @Walls10 Well, he DOES own 10%+ of $IRWD and $INVA. So it's not like he's opposed to it. He may currently have strategic reasons to not want to become an insider, however. Truth is, we really just don't know what he wants or is going to do.